7 DURABOLIN® DESCRIPTION—Durabolin is nandrolone A*-androstene-178-ol-3-one-8-phenyl for intramuscular injection phenpropionate propionate). in 5 cc. vials and (19-nor- It is available 1 cc. ampuls, each cc. providing 25 mg. of nandrolone phenpropionate dissolved in sesame oil, The structural formula for Durabolin is shown below: 18 O | CH; O—€ Ha He =C!-C DURABOLIN (nandrolone phenpropionate) PROPERTIES— The action of Durabolin is primarily anabolic (protein-sparing). It promotes body tissue-building processes and reverses catabolic or tissue-depleting processes. In addition, Durabolin has a very favorable anabolic-androgenic effect ratio. The deletion of the CH3 group from the C-19- position has resulted in reduction of its androgenic properties and retention and enhancement of its anabolic, tissue-building properties. Thus it is possible to employ doses that provide significant anabolic effects without undesired androgenic effects. Durabolin offers prolonged action, owing to its phenylpropionate esterification which causes slow degradation of the steroid in the body. The action is thus prolonged for from one to three weeks, depending upon the dosage employed. INDICATIONS— Durabolin is useful in the treatment of those conditions in which a potent tissue-building or protein-sparing action is desired. lts principal uses are to induce weight gain and well-being by virtue of its anabolic action. Durabolin therapy is most efective when combined with a good dietary regimen. Durabolin's prolonged anabolic effects have been demonstrated in pre- and postoperative treatment, retarded growth and development in children, osteoporosis, uremia, inoperable mammary carcinoma, cachexia during convalescence, debility states, weight loss, corticoid- induced catabolic states, osteogenesis imperfecta and myopathies. DOSAGE—Durabolin is intended for intramuscular injection. For general anabolic effects in adults, the average dosage recommended is 25 mg. weekly, with variations depending upon the condition and the patient under treatment. If preferred, 50 mg. may be given once every two weeks. For children under seven, the dosage is reduced to 10 mg. or less weekly; for infants, from | to 5 mg. weekly. Durabolin should be regarded as adjunctive therapy, and effort should be made to diagnose and treat the primary cause of the disturbance. Adequate quantifies of nutrients, including vitamins, minerals and proteins should be consumed by the patient in order to obtain maximal therapeutic effects. Patients whose appetites and food habits are disturbed by neurotic tendencies or other psychic disturbances should have special attention directed toward correction of the cause of malnutrition. Since signs of anabolic properties (especially weight gain) are believed best brought out by periodic treatment, it is recommended that Durabolin be given for continuous periods of up to twelve weeks. If at the end of a four week rest period the indications for Durabolin continue, this treatment may then be resumed. | | | |